Core Viewpoint - The company has successfully completed the Phase II clinical trial for the new drug XTMAB targeting lung nodules, with positive results reported. The Phase III clinical trial is expected to commence in the first quarter of next year [1]. Group 1 - The Phase II clinical trial for XTMAB has concluded with favorable outcomes [1]. - The anticipated start date for the Phase III clinical trial is projected for the first quarter of next year [1].